Deal Finally Unlocks NHS Access to ITF's Duchenne Drug

Why It Matters

The decision expands NHS treatment options for ambulatory boys with DMD, potentially improving outcomes, yet it leaves the most severe patients without access, underscoring equity challenges in rare‑disease care.

Key Takeaways

• Duvyzat approved for >500 NHS ambulatory Duchenne patients.
• Immediate coverage via Innovative Medicines Fund, routine funding pending.
• NICE guidance excludes non‑ambulatory patients, sparking advocacy criticism.
• Phase 3 EPIDYS trial showed slower progression over 18 months.
• Ends postcode lottery after Scotland’s earlier approval.

Pulse Analysis

Duchenne muscular dystrophy remains one of the most devastating pediatric neuromuscular disorders, affecting roughly one in 3,500 newborn boys and limiting life expectancy to around 30 years. Therapeutic options have been scarce, with only two drugs previously approved in the UK. Duvyzat, an oral histone deacetylase inhibitor, targets muscle regeneration pathways, aiming to preserve muscle mass and reduce inflammation. The EPIDYS phase‑3 trial, involving 120 participants, demonstrated a statistically significant slowdown in functional decline, notably in stair‑climbing time, over an 18‑month period.

NICE’s recent draft guidance marks a pivotal shift for the NHS, as the Innovative Medicines Fund will cover Duvyzat immediately, bypassing the lengthy budget‑impact negotiations that often delay rare‑disease therapies. This rapid funding mechanism, coupled with the forthcoming routine reimbursement plan, resolves the “postcode lottery” that left English patients waiting while Scotland’s Medicines Consortium had already approved the drug. By aligning England with Scotland, the NHS now offers a consistent standard of care for ambulatory DMD patients across the United Kingdom.

However, the guidance’s restriction to ambulatory patients—those who can walk or stand—excludes a substantial subset of the DMD population who have lost mobility. Advocacy groups, led by Duchenne UK, argue that this creates a new tier of inequality and urge policymakers to reconsider the eligibility criteria. The controversy highlights broader challenges in balancing cost‑effectiveness thresholds with the urgent needs of rare‑disease communities. Future negotiations may expand access, especially as real‑world data on Duvyzat’s efficacy and safety accumulate, potentially reshaping reimbursement frameworks for high‑cost orphan drugs.